Company: CDT
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022373
Chunk: 43

Company: CDT Equity Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 43
---
and $8 thousand as long-term. As of September 30, 2025, the Company has $0.2 million in future minimum lease payments remaining.

    25

15.
Segments

The
Company has one operating segment focused on the research and development of clinical assets. The accounting policies of the single operating
segment are identical to those described in Note 1. The Chief Operating Decision Maker (“CODM”), which the Company has identified
as Dr. Andrew Regan, Chief Executive Officer, manages the Company’s operations on a consolidated basis, assesses performance for
the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the condensed consolidated
statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and non-cash
lease expense are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the consolidated
statements of cash flows. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated
assets reviewed by the CODM and are reported on the consolidated statements of cash flows.

The
CODM uses consolidated net loss and budget-to-actual variances to assess the operating segment’s performance and determine whether
the Company is progressing towards its goals.

The
following table presents specific financial data for the Company’s reportable segment (in thousands):

Schedule
of Financial Data for the Company’s Reportable Segment 

    Three Months ended September 30,  
    Nine Months ended  September 30, 
  
    (Dollar amounts in thousands) 
    2025  
    2024  
    2025  
    2024 
  
    Operating expenses: 

    Research & development expenses-clinical asset development 
    $209  
    $3,093  
    $620  
    $3,246 
  
    Research & development expense – related parties 
     1,023  
     -  
     3,388  
     - 
  
    Research & development expense – related parties-digital assets 
     300  
     -  
     300  
     - 
  
    General and administrative expenses – legal & professional fees 
     1,809  
     423  
     3,441